Literature DB >> 28581458

When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?

C Solano1,2, E Giménez3, J L Piñana1, J C Hernández-Boluda1, P Amat1, V Vinuesa3, D Navarro3,4.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28581458     DOI： 10.1038/bmt.2017.109

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  12 in total

Review 1.  How we treat cytomegalovirus in hematopoietic cell transplant recipients.

Authors:  Michael Boeckh; Per Ljungman
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

2.  Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.

Authors:  P Ljungman; R de la Camara; C Cordonnier; H Einsele; D Engelhard; P Reusser; J Styczynski; K Ward
Journal:  Bone Marrow Transplant       Date:  2008-06-30       Impact factor: 5.483

3.  Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies.

Authors:  Beatriz Muñoz-Cobo; Carlos Solano; Elisa Costa; Dayana Bravo; María Ángeles Clari; Isabel Benet; María José Remigia; Juan Montoro; David Navarro
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-24       Impact factor: 5.742

4.  Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain.

Authors:  Carlos Solano; Rafael de la Cámara; Lourdes Vázquez; Javier López; Estela Giménez; David Navarro
Journal:  J Clin Microbiol       Date:  2015-06-10       Impact factor: 5.948

5.  Comparison of the new Abbott Real Time CMV assay and the Abbott CMV PCR Kit for the quantitation of plasma cytomegalovirus DNAemia.

Authors:  María Ángeles Clari; Dayana Bravo; Elisa Costa; Beatriz Muñoz-Cobo; Carlos Solano; María José Remigia; Estela Giménez; Omar J Benmarzouk-Hidalgo; Pilar Pérez-Romero; David Navarro
Journal:  Diagn Microbiol Infect Dis       Date:  2012-11-20       Impact factor: 2.803

6.  Management of cytomegalovirus infection in haemopoietic stem cell transplantation.

Authors:  Vincent Emery; Mark Zuckerman; Graham Jackson; Celia Aitken; Husam Osman; Anthony Pagliuca; Mike Potter; Karl Peggs; Andrew Clark
Journal:  Br J Haematol       Date:  2013-05-06       Impact factor: 6.998

7.  Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: does it have any clinical value?

Authors:  Estela Giménez; Beatriz Muñoz-Cobo; Carlos Solano; Paula Amat; David Navarro
Journal:  J Clin Microbiol       Date:  2013-11-27       Impact factor: 5.948

8.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Authors:  H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas
Journal:  Transplantation       Date:  1974-10       Impact factor: 4.939

9.  Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy.

Authors:  Paul D Griffiths; Emily Rothwell; Mohammed Raza; Stephanie Wilmore; Tomas Doyle; Mark Harber; James O'Beirne; Stephen Mackinnon; Gareth Jones; Douglas Thorburn; Frank Mattes; Gaia Nebbia; Sowsan Atabani; Colette Smith; Anna Stanton; Vincent C Emery
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

10.  Viral disease prevention after hematopoietic cell transplantation.

Authors:  J Zaia; L Baden; M J Boeckh; S Chakrabarti; H Einsele; P Ljungman; G B McDonald; H Hirsch
Journal:  Bone Marrow Transplant       Date:  2009-10       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.